Form 4: Amneal Pharmaceuticals Director Equity Transaction

Director Paul M. Meister acquired 48,747 shares of Amneal Pharmaceuticals through the vesting of restricted stock units.

Summary

• Director Paul M. Meister exercised 48,747 restricted stock units (RSUs) on May 7, 2026, converting them into Class A Common Stock.
• The reporting person was granted an additional 30,837 RSUs on May 6, 2026.
• Following these transactions, the director holds 832,800 shares of Class A Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation and equity management.

Positives

• Director maintains a significant equity stake of 832,800 shares, aligning interests with shareholders.

Negatives

• None noted.

Risks

• Future vesting of the newly granted 30,837 RSUs is subject to the timing of the annual meeting of stockholders.

Future Outlook

The director holds 30,837 unvested restricted stock units which are scheduled to vest based on the timing of the next annual meeting of stockholders and the first anniversary of the grant date.

Management Comments

• Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Industry Context

StockSavvy.ai notes that routine equity vesting for directors is standard corporate governance practice in the pharmaceutical sector, reflecting typical long-term incentive compensation structures.

Comparison to Industry Standards

• The transaction follows standard SEC reporting requirements for executive and director compensation.
• Equity-based compensation for board members is consistent with peer pharmaceutical companies like Teva or Viatris.

Stakeholder Impact

• No material impact on shareholders as this is a standard equity compensation event.

Next Steps

• Vesting of the 30,837 restricted stock units granted on May 6, 2026, subject to the annual meeting schedule.

Key Dates

Keywords

Amneal Pharmaceuticals, AMRX, Insider Trading, Form 4, Equity Compensation, Director Ownership